Loading clinical trials...

RECRUITINGPHASE1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

A Phase I Clinical Study Comparing the Relative Bioavailability, Safety and Tolerability of the First-generation and Second-generation Formulations of HRS9531 Tablets and Exploring the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Escalation of the Second-generation Formulation

NCT07150962•Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic characteristics of the second-generation formulation in terms of single-dose escalation.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;
•2. Male subjects aged 18-55 years on the date of signing informed consent (inclusive);
•3. Body weight ≥65 kg, body mass index (BMI) within the range of 24.0-35.0 kg/m2 (inclusive);
•4. The weight change within the previous 3 months should not exceed 5 kilograms.
•5. Based on the patient's past medical history, physical examination, vital signs, laboratory tests and electrocardiogram (ECG) examinations, the researchers determined that the overall overweight and obese subjects were included.

Exclusion Criteria

•1. Those who are known or suspected to be allergic to any component of the investigational drug or related products; or those who have a history of multiple or severe allergies to drugs or foods, or a history of severe immediate allergic reactions;
•2. Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study;
•3. Having a history of hypertension or when the researchers determine during the screening that the blood pressure is abnormal and has clinical significance;
•4. Those with a history of obvious gastrointestinal diseases or related symptoms (such as nausea, vomiting, heartburn sensation or diarrhea), conditions that affect gastric emptying (such as pyloric stenosis), or who have undergone any gastrointestinal surgery (such as weight loss surgery; except for intestinal polyp resection and appendectomy), or who had acute diarrhea within the previous 7 days; diarrhea is defined as watery stools and/or more than 3 bowel movements per day;
•5. Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing;
•6. Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing;
•7. Hepatitis B surface antigen (HBsAg), HIV antibody, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
•8. Those who have a history of drug abuse or drug use, or who have a positive result in the urine drug screening test during the screening period;
•9. Heavy drinkers (average weekly alcohol consumption of ≥ 14 units in the six months prior to screening: 1 unit of beer = 285 mL, or spirits = 25 mL, or wine = 100 mL; average daily smoking ≥ 5 cigarettes); those unable to quit smoking and drinking during the trial; those with positive alcohol blood tests.

Locations (1)

The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Key Dates

Start Date

October 15, 2025

Primary Completion Date

February 1, 2026

Completion Date

September 1, 2026

Last Updated

November 17, 2025

Enrollment

168

ESTIMATED participants

Conditions

Overweight or Obesity

Interventions

HRS-9531 Tablet

DRUG

Contacts

Jingjing Wang

CONTACT

+86-0518-82342973 jingjing.wang@hengrui.com

Tong Zhang

CONTACT

+86-0518-82342973 tong.zhang.tz58@hengrui.com

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400

Part A: Healthy Part B: Overweight or Obesity

View study

RECRUITINGPHASE3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857

Overweight or ObesityAtrial Fibrillation

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Inclusion Criteria

Exclusion Criteria

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Weight Reduction in CLBP

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients